| abstract |
Compounds of formula (I), wherein the ring with the increment (N-A) can be 5, 6 or 7-membered and can also contain an oxygen or sulfur atom or a C-C double bond, with the exception of the 1,4-benzoxazepine skeleton, A represents a carbonyl or sulfonyl group, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, a carbon atom or CH and the bond between Y and Z can also be a double bond, n means the number 2, 3 or 4, R1 can be a hydrogen atom, halogen or a C¿1?-C4-alkyl, trifluoromethyl, hydroxy, C1-C4-alkoxy or amino group and R?2¿ represents a phenyl, pyridyl or pyrazinyl group which is optionally mono or di-substituted by C¿1?-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which can be anellated with a benzole nucleus which can be mono or di-substituted by halogen atoms, C1-C4-alkyl, hydroxy, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups and can optionally contain 1 nitrogen atom, or with a 5 or 6-membered ring which can contain 1 to 2 oxygen atoms; and physiologically compatible salts of these compounds show affinity for the 5-HT1A receptor and are suitable for treating cerebral ischaemia. |